Riskpilot← Back to searchSign inGet full accessEliva IVF AB
ABActiveOrg 5592487416Saltängsvägen 20Medical specialists activities · NACE 8622Est. 20200 employees
Revenue 2025
SEK 35,2M
+37% vs 2024
EBITDA margin
29.0%
+954% vs 2024
Equity ratio
30.8%
Financial strength
Net profit 2025
SEK 7,7M
+7146% vs 2024
| Revenue | SEK 35,2M | +37% |
| EBITDA | SEK 10,2M | +954% |
| Net profit | SEK 7,7M | +7146% |
| Total assets | SEK 31,5M | +35% |
| Equity | SEK 9,7M | +377% |
| Employees | 0 | — |
Legal name
Eliva IVF AB
Org number
5592487416
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
19 mars 2020
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att utföra IVF och andra medicinska behandlingar och att tillhandahålla personal som utför sådana behandlingar liksom att förvalta aktier och utdelningar och därmed förenlig verksamhet.
Address
Saltängsvägen 20
Email
ken@elivaclinic.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 19 132 | 14 912 | 13 136 | 25 683 | 35 178 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 140 | 2 112 | 3 542 | 966 | 10 186 |
| Depreciation & amort. | −28 | −110 | −129 | −247 | −463 |
| EBIT | 112 | 2 001 | 3 413 | 720 | 9 722 |
| Net financials | 2 | −1 | −0 | 15 | −4 |
| Profit before tax | 114 | 0 | 2 263 | 135 | 9 719 |
| Tax | −24 | −0 | −445 | −29 | −2 034 |
| Net profit | 90 | 0 | 1 818 | 106 | 7 684 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 18 882 | 17 510 | 12 612 | 23 337 | 31 546 |
| Equity | 115 | 115 | 1 933 | 2 039 | 9 724 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 18 767 | 17 395 | 10 678 | 21 297 | 21 823 |
| Total debt | 18 767 | 17 395 | 10 678 | 21 297 | 21 823 |
EBITDA margin
29.0%
This company
15.8%
Market median
+84% vs market
20212025
Equity ratio
30.8%
This company
38.2%
Market median
+19% vs market
20212025
Return on equity
79.0%
This company
18.4%
Market median
+329% vs market
20212025
Net profit margin
21.8%
This company
8.1%
Market median
+169% vs market
20212025
Asset turnover
1.12×
This company
1.12×
Market median
+0% vs market
20212025
Debt / equity
2.24×
This company
0.62×
Market median
-261% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-03-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PW Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Eliva AB
Eliva IVF AB Board members of Eliva IVF AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patricie Weis | Audit | 0 companies |
| Linus Lunde Eriksson | Deputy Board Member | 0 companies |
| Kenneth Lunde Sørensen | Board of Directors | 0 companies |